Suppr超能文献

淋巴因子激活的杀伤现象剖析。外周血自然杀伤细胞和T淋巴细胞对细胞溶解的相对贡献。

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

作者信息

Phillips J H, Lanier L L

出版信息

J Exp Med. 1986 Sep 1;164(3):814-25. doi: 10.1084/jem.164.3.814.

Abstract

In vitro culture of human peripheral blood lymphocytes in IL-2 results in the generation of cytotoxic cells that can lyse fresh and cultured solid tumor cells, as well as hematopoietic tumor cell lines, without deliberate immunization or MHC restriction. This has been referred to as the lymphokine activated killer (LAK) phenomenon. Here, we show that the majority of this activity is mediated by NK cells that express the Leu-19 (NKH-1) antigen, but do not express CD3. The precursor of this effector population also expressed the phenotype CD3-, Leu-19+. Peripheral blood CD3+ T lymphocytes contributed little to the LAK phenomenon, although low levels of non-MHC restricted cytotoxicity against hematopoietic tumor cell targets were mediated by a subset of CD3+ T lymphocytes that coexpressed the Leu-19 antigen. These studies clearly indicated that the LAK phenomenon is not mediated by a unique LAK cell, but is mediated mainly by IL-2-activated peripheral blood NK cells.

摘要

在白细胞介素-2(IL-2)存在的情况下对人外周血淋巴细胞进行体外培养,会产生细胞毒性细胞,这些细胞能够裂解新鲜的和培养的实体瘤细胞以及造血肿瘤细胞系,无需特意免疫或受主要组织相容性复合体(MHC)限制。这一现象被称为淋巴因子激活的杀伤细胞(LAK)现象。在此,我们表明这种活性的大部分是由表达Leu-19(NKH-1)抗原但不表达CD3的自然杀伤(NK)细胞介导的。这种效应细胞群体的前体细胞也表达CD3-、Leu-19+表型。外周血CD3+ T淋巴细胞对LAK现象贡献很小,尽管共表达Leu-19抗原的CD3+ T淋巴细胞亚群介导了对造血肿瘤细胞靶标的低水平非MHC限制的细胞毒性。这些研究清楚地表明,LAK现象不是由独特的LAK细胞介导的,而是主要由IL-2激活的外周血NK细胞介导的。

相似文献

引用本文的文献

5
Advanced T and Natural Killer Cell Therapy for Glioblastoma.用于胶质母细胞瘤的先进T细胞和自然杀伤细胞疗法。
J Korean Neurosurg Soc. 2023 Jul;66(4):356-381. doi: 10.3340/jkns.2022.0267. Epub 2023 Jan 2.
6
Next Generation Natural Killer Cells for Cancer Immunotherapy.下一代自然杀伤细胞用于癌症免疫治疗。
Front Immunol. 2022 Jun 2;13:886429. doi: 10.3389/fimmu.2022.886429. eCollection 2022.
9
NK cells for cancer immunotherapy.自然杀伤细胞用于癌症免疫疗法。
Nat Rev Drug Discov. 2020 Mar;19(3):200-218. doi: 10.1038/s41573-019-0052-1. Epub 2020 Jan 6.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验